Industry Spotlight: Elorac

In early June, CLF CEO, Susan Thornton talked with Dr. Scott B. Phillips, Vice President, Scientific Affairs of Elorac, Inc. Elorac is currently engaged in a Phase III clinical trial for topical naloxone, which targets itch in cutaneous lymphoma. Listen to the discussion to learn more about this innovative approach to managing the intense itch associated with the disease. 

Designed and built by Giant Rabbit.